Business
RSV Challenge Model Delivers Positive Results
RSV Challenge Model Delivers Positive Results.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 3913C hVIVO plc 17 June 2019 \n\nhVIVO plc\n(\"hVIVO\" or the \"Company\")\n \nhVIVO RSV challenge model delivers positive results for novel therapy\n \n· Human Challenge Study conducted by hVIVO using its industry leading RSV challenge model delivers positive results for Enanta's novel N-protein inhibitor EDP-938\n \nLondon, UK - 17 June 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral challenge, acknowledges the announcement by Enanta Pharmaceuticals, Inc. of positive topline results from an RSV challenge study. The study demonstrated that Enanta's novel N-protein inhibitor, EDP-938, achieved highly statistically significant (p<0.001) reductions in viral load and in resolution of clinical symptoms compared to placebo in healthy adults infected with respiratory syncytial virus (RSV). The study was conducted at hVIVO's specialist clinical facility in London, using its industry leading RSV challenge study protocol.\n \nDr Trevor Phillips, Executive Chairman, commented:\n\"We are pleased to have been able to support Enanta in the development of this novel therapy. These positive clinical proof of concept results support the further development of EDP-938. The study conducted by hVIVO highlights the value that can be obtained from challenge studies to rapidly establish clear indications of clinical efficacy and dose-response and deliver supporting safety data in a cost-effective controlled study at an early stage of a product's development. The data also further validate the value of our RSV challenge model that we believe to be the only such RSV model currently commercially available.\n \nThe Company's contract pipeline is experiencing a strong demand for RSV challenge study services, which is reflective of the unmet medical need that companies are addressing and the results of this study are further endorsement of the value of the hVIVO challenge model in RSV and the benefit of viral challenge models in clinical development in general.\"\n \nFor further information please contact: \n \n\n\n\nhVIVO plc \n\n\n\n\n\n\n\nTrevor Phillips (Executive Chairman) \n\n\n+44 207 756 1300\n\n\n\n\nShelley Fraser (Finance Director & Company Secretary)\nFleur Wood ...